Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.

INCLUSION CRITERIA: PAH and PH-IPF * WHO Functional Class (or equivalent classification) II - IV. * Subjects using supplemental oxygen must be receiving a stable course of therapy for a minimum of 14 days prior to study drug administration. * All subjects' oxygen saturation must be \> or = to 88% at time of treatment * Echocardiogram within 6 months of baseline showing no signs of clinically significant left sided heart disease * Females of child-bearing potential with a negative urine pregnancy test, or a documented surgical sterilization, or is post-menopausal prior to administration of investigational product. Females of childbearing potential must be practicing adequate birth control. PAH (WHO Group 1) ONLY-Inclusion * Documented diagnosis of WHO Group 1 PAH, (limited to, idiopathic, heritable, drug and toxin induced, associated with connective tissue disease, portal hypertension, repaired congenital heart disease, HIV); documented by a previous RHC and hemodynamics consistent with PAH, WHO Group 1 * Pulmonary Function Testing within 6 months prior to screening/enrollment shows no evidence of interstitial lung disease (TLC\<70%) or obstructive lung disease (FEV1/FVC ratio \<50%) * Receiving a stable course of approved PAH oral mono therapies for a minimum of 14 days prior to treatment period * Must be 18-80 year of age PH-IPF (WHO Group 3) ONLY-Inclusion * Documented diagnosis of probable or definite IPF using ATS/ERS criteria * Previous transbronchial biopsy, if performed, shows no features to support a definitive alternative diagnosis * Previous bronchoalveolar lavage, if performed, shows no features that provides an alternative diagnosis * FVC \> or = 40% within 6 months of baseline visit * Diagnosis of PH based on hemodynamic requirements * Age 40-85. * Diagnosis of IPF \> or = 3 months prior to study drug administration * Diagnosis of PH based on the following hemodynamic criteria (PAPm \> or = 25 mmHg (at rest) / PCWP or LVED \< or =15 mmHg and / PVR \>3 Wood Units) EXCLUSION CRITERIA: PAH and PH-IPF * Have any other disease associated with pulmonary hypertension (i.e. Group II, IV or V). * Documented uncontrolled systemic hypertension. * Left ventricular ejection fraction (LVEF) \< 40%. * Have chronic kidney disease stage IV or worse, or requires dialysis. * Be receiving an investigational drug, have in place an investigational device, or have participated in an investigational drug study within past 30 days. * Have had an atrial septostomy. * Have anemia or any other ongoing condition that would interfere with the interpretation of study assessments. * Have any serious or life-threatening disease other than conditions associated with PAH or PH-IPF (e.g. malignancy requiring aggressive chemotherapy, renal dialysis, etc.) * Significant, ongoing alcohol or drug abuse, or unstable psychiatric status. * Receiving inhaled or parenteral prostacyclins or a non-approved combination of approved oral PAH therapy. * Pregnant or lactating subjects PAH (WHO Group 1) ONLY-Exclusion * Have had any changes to chronic therapy (including but not limited to oxygen, a different category of vasodilator, a diuretic, digoxin) for PAH added within 14 days of study drug administration. Anticoagulants are allowed to be discontinued per institutional standard of care. * History of untreated sleep apnea within three months of study drug administration. * History of hemodynamically significant left-sided heart disease or evidence of left-sided heart disease. PH-IPF (WHO Group 3) ONLY-Exclusion * Diagnosis of PH primarily due to etiology other than IPF. * FEV/FVC ratio \< 60% documented within 6 months of baseline visit. * Hospitalization for acute exacerbation of IPF within 30 days of baseline visit. * Recent active pulmonary or upper respiratory tract infection. * Receiving any approved PAH therapy within 30 days of study drug administration.